Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Skin protectant monograph fixes

This article was originally published in The Tan Sheet

Executive Summary

FDA technical amendment to the Skin Protectant Drug Products Final Monograph corrects an "approved as of" date for ingredients published with the monograph last year (1"The Tan Sheet" June 9, 2003, p. 6). Final document had an incorrect "approved as of" date of May 7, 1991, rather than Nov. 10, 1993, FDA says in a Federal Register notice Aug. 18. Published monograph also included select paragraphs in the wrong section, FDA adds...

You may also be interested in...



Skin Protectant Final Rule Allows Cross-Monograph Ingredient Combinations

The OTC Skin Protectant Final Monograph covering products for minor cuts, scrapes, burns, chapped skin and lips, poison ivy, poison oak, poison sumac and insect bites allows for certain cross-monograph ingredient combinations, according to the rule published in the 1Federal Register June 4

Pipeline Watch: Five Approvals And 15 Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Spring Launch For Germany’s Digital Strategy

Interested parties have been consulted, workshop findings noted and online surveys completed; the drafting of Germany’s digital health strategy is now underway.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel